Kadin D V, Chumak B A, Filippov A E, Shustov S B
1S.. Kirov St. Petersburg Military medical academy, St. Petersburg, Russia; 2St.Petersburg State University, St. Petersburg, Russia.
Kardiologiia. 2015 Aug;55(8):26-29. doi: 10.18565/cardio.2015.8.26-29.
Trimetazidine is a metabolic agent of proven efficacy in improving myocardial ischemia and angina. A comparative international multicenter randomized trial, assessed anti-anginal anti ischemic efficacy and safety of Trimetazidine (60 mg/d) and Thiotriazoline (600 mg/d) in symptomatic patients with chronic ischemic heart disease receiving the first line therapy. The study assessed the efficacy of the two drugs on total exercise duration, time to 1-mm ST segment depression, the number of angina attacks and nitroglycerin tablets consumed amount. Both drugs have demonstrated clinical efficacy equal for all primary and secondary endpoints.